Eli Lilly and Company (NYSE:LLY) Shares Sold by Kapstone Financial Advisors LLC

Kapstone Financial Advisors LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 67.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 252 shares of the company’s stock after selling 514 shares during the period. Kapstone Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $203,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Eli Lilly and Company by 76.7% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 562 shares of the company’s stock valued at $498,000 after buying an additional 244 shares in the last quarter. Emerald Advisers LLC boosted its holdings in shares of Eli Lilly and Company by 75.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,873 shares of the company’s stock valued at $1,659,000 after buying an additional 804 shares in the last quarter. BSW Wealth Partners boosted its holdings in shares of Eli Lilly and Company by 4.3% in the 3rd quarter. BSW Wealth Partners now owns 3,236 shares of the company’s stock valued at $2,867,000 after buying an additional 134 shares in the last quarter. Lansing Street Advisors boosted its holdings in shares of Eli Lilly and Company by 3.3% in the 3rd quarter. Lansing Street Advisors now owns 648 shares of the company’s stock valued at $575,000 after buying an additional 21 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in shares of Eli Lilly and Company by 14.5% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 826,944 shares of the company’s stock valued at $732,623,000 after buying an additional 104,801 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.0 %

Shares of Eli Lilly and Company stock opened at $930.22 on Tuesday. The company has a market cap of $882.01 billion, a P/E ratio of 79.44, a PEG ratio of 1.40 and a beta of 0.42. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The firm has a fifty day moving average of $817.56 and a two-hundred day moving average of $848.11.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 51.24%.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company decreased their price target on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Citigroup decreased their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.